Published in:
Open Access
01-12-2019 | Antiviral Agents | Case report
Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents
Authors:
Taotao Yan, Jiuping Wang, Juan Li, Shan Fu, Yi Chen, Chunhua Hu, Rou Zhang, Zhen Tian, Fahui Zhao, Jun Dong, Jinfeng Liu, Yuan Yang, Tianyan Chen, Yingren Zhao, Yingli He
Published in:
BMC Infectious Diseases
|
Issue 1/2019
Login to get access
Abstract
Background
Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.
Case presentation
Thirty-three patients with stage 5 CKD and hepatitis C virus (HCV) infection from 2 hemodialysis centers accepted sofosbuvir based treatment as we reported previously. Serum potassium concentrations were tested every 4 weeks or on demand. Ten of 33 patients showed recurrence of hyperkalemia. We summarized the characteristics of hyperkalemia occurrence in these 10 patients. Overall, 24 episodes of hyperkalemia were observed in these 10 patients, 21 were under treatment and 3 were after treatment. Patients with or without hyperkalemia before sofosbuvir treatment didn’t show significantly differences in the median frequencies of hyperkalemia episodes during the observation period (3.5 vs. 2, p = 0.264).
Conclusions
Patients with stage 5 CKD and HCV infection treated with sofosbuvir based regimens, even halved sofosbuvir, should be taken caution and closely monitoring serum potassium and renal function is necessary.